We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
PURITAN MEDICAL

Download Mobile App





Prevencio Presents AI-Driven Platform for Medical Diagnostic Test Development

By LabMedica International staff writers
Posted on 27 Jul 2023

Prevencio, Inc. More...

(Kirkland, WA, USA) is showcasing its leading-edge, artificial intelligence (AI)-powered HART platform and blood tests at AACC 2023.

Prevencio has announced the culminative presentation of patient data demonstrating that its AI-empowered HART blood tests exhibit high accuracy across a diverse patient demographic, including those affected by diabetes, chronic kidney disease, hypertension, obesity, coronary heart disease, heart failure, chronic total occlusion (CTO) of the heart arteries, and Kawasaki disease. The HART platform is disease agnostic, thereby allowing the development of diagnostics that extend beyond cardiac diseases. Presently, Prevencio's two primary tests, HART CVE and HART CADhs, are accessible to medical professionals for patient use. HART CVE calculates a patient's one-year risk for a heart attack, stroke, or cardiovascular death, whereas HART CADhs evaluates if a patient has a blockage in the heart arteries, indicating an imminent risk of a heart attack. Researchers from Massachusetts General Hospital (MGH, Boston, MA, USA) tested more than 1,250 patients undergoing coronary or peripheral angiography to collaborate in the development and validation of the AI-driven HART platform which has produced seven highly accurate, algorithmic multiple protein blood tests.

“It is impressive the HART tests provide robust accuracy amongst a wide range of patients,” said James L. Januzzi, MD, a practicing cardiologist at MGH, and principal investigator in development, validation, and ongoing testing of six of the seven HART tests. “With the rapid rise in cardiovascular disease, better tools to recognize risk and intervene proactively are needed. Our data suggest that AI-derived, multi-protein, algorithmically scored blood tests may be useful to individualize cardiac risk assessment and foster aggressive primary and secondary cardiovascular prevention. We are especially excited with our most recent data demonstrating the accuracy of HART CVE in assessing risk in patients with total chronic occlusion of the coronary arteries and look forward to using the HART platform to develop additional clinical applications and diagnostic tests.”

Related Links:
Prevencio, Inc.
MGH 


New
Gold Member
Quality Control Material
iPLEX Pro Exome QC Panel
3-Part Differential Hematology Analyzer
Swelab Alfa Plus Sampler
New
Modular Hemostasis Automation Solution
CN Track
New
Automatic Hematology Analyzer
LABAS F9000
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








DIASOURCE (A Biovendor Company)

Channels

Molecular Diagnostics

view channel
Image: The discovery of early markers for ovarian cancer that would have improved sensitivity could aid detection (Photo courtesy of Adobe Stock)

Highly Accurate Biomarkers Could Detect Ovarian Cancer Before Clinical Diagnosis

Ovarian cancer is a deadly and challenging disease, primarily because early detection is difficult. Most women (70-75%) are diagnosed only after the cancer has already spread, which significantly reduces... Read more

Hematology

view channel
Image: CitoCBC is the world first cartridge-based CBC to be granted CLIA Waived status by FDA (Photo courtesy of CytoChip)

Disposable Cartridge-Based Test Delivers Rapid and Accurate CBC Results

Complete Blood Count (CBC) is one of the most commonly ordered lab tests, crucial for diagnosing diseases, monitoring therapies, and conducting routine health screenings. However, more than 90% of physician... Read more

Immunology

view channel
Image: CellLENS enables the potential precision therapy strategies against specific immune cell populations in the tissue environment (Photo courtesy of MIT)

New AI System Uncovers Hidden Cell Subtypes to Advance Cancer Immunotherapy

To produce effective targeted therapies for cancer, scientists need to isolate the genetic and phenotypic characteristics of cancer cells, both within and across different tumors. These differences significantly... Read more

Technology

view channel
Image: The Check4 gene-detection platform (Photo courtesy of IdentifySensors)

Electronic Biosensors Used to Detect Pathogens Can Rapidly Detect Cancer Cells

A major challenge in healthcare is the early and affordable detection of serious diseases such as cancer. Early diagnosis remains difficult due to the complexity of identifying specific genetic markers... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.